Plain-English translation of NCT07043686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether Cerebrolysin, a medication made from brain proteins and amino acids, can help people recover better after an acute ischemic stroke (a stroke caused by a blood clot). All participants will receive the best standard care for stroke, but some will also receive the medication during their early recovery period. Researchers want to see if the medication helps reduce disability and improves how well people function at the time they leave the hospital and 90 days later.
Stroke recovery has improved significantly over the years with new treatments, but doctors are still looking for ways to help people recover even better, especially those with moderate to severe stroke symptoms. This trial will help determine whether this medication can safely and effectively boost recovery when used alongside standard care.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive standard stroke care in the hospital. You will be randomly assigned to either receive the medication along with standard care, or standard care alone. Throughout your hospital stay and at a follow-up visit 90 days after your stroke, doctors will measure how well you are recovering using standard tests and assessments. The study involves about 30 patients total at this medical center.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Slovenia
Sponsor
University Medical Centre Ljubljana
Enrollment target
~30 participants
Started
June 2025
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matija Zupan, MD, PhD
University Medical Centre Ljubljana
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.